CY1122508T1 - Παρασκευευασματα για θεραπεια gd2 θετικου καρκινου - Google Patents
Παρασκευευασματα για θεραπεια gd2 θετικου καρκινουInfo
- Publication number
- CY1122508T1 CY1122508T1 CY20201100048T CY201100048T CY1122508T1 CY 1122508 T1 CY1122508 T1 CY 1122508T1 CY 20201100048 T CY20201100048 T CY 20201100048T CY 201100048 T CY201100048 T CY 201100048T CY 1122508 T1 CY1122508 T1 CY 1122508T1
- Authority
- CY
- Cyprus
- Prior art keywords
- patient
- positive cancer
- compositions
- treating
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201314086696A | 2013-11-21 | 2013-11-21 | |
| EP13193953.0A EP2875827A1 (en) | 2013-11-21 | 2013-11-21 | Preparations and methods for treating a GD2 positive cancer |
| CA2834000A CA2834000A1 (en) | 2013-11-21 | 2013-11-21 | Method for treating a gd2 positive cancer |
| US14/182,776 US10294305B2 (en) | 2012-06-18 | 2014-02-18 | Method for treating a GD2 positive cancer |
| EP14802642.0A EP3071220B1 (en) | 2013-11-21 | 2014-11-21 | Preparations for treating a gd2 positive cancer |
| PCT/EP2014/075315 WO2015075194A1 (en) | 2013-11-21 | 2014-11-21 | Preparations and methods for treating a gd2 positive cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122508T1 true CY1122508T1 (el) | 2021-05-05 |
Family
ID=53179006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100048T CY1122508T1 (el) | 2013-11-21 | 2020-01-21 | Παρασκευευασματα για θεραπεια gd2 θετικου καρκινου |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10995147B2 (enExample) |
| EP (2) | EP3620173A1 (enExample) |
| JP (2) | JP6693873B2 (enExample) |
| AU (2) | AU2014351796B2 (enExample) |
| CA (1) | CA2930285A1 (enExample) |
| CY (1) | CY1122508T1 (enExample) |
| DK (1) | DK3071220T3 (enExample) |
| EA (1) | EA201691055A1 (enExample) |
| ES (1) | ES2768649T3 (enExample) |
| HR (1) | HRP20200128T1 (enExample) |
| HU (1) | HUE047920T2 (enExample) |
| LT (1) | LT3071220T (enExample) |
| NZ (1) | NZ720273A (enExample) |
| PL (1) | PL3071220T3 (enExample) |
| PT (1) | PT3071220T (enExample) |
| RS (1) | RS59817B1 (enExample) |
| SI (1) | SI3071220T1 (enExample) |
| SM (1) | SMT202000027T1 (enExample) |
| WO (1) | WO2015075194A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013189516A1 (en) | 2012-06-18 | 2013-12-27 | Apeiron Biologics Ag | Method for treating a gd2 positive cancer |
| EA201691055A1 (ru) | 2013-11-21 | 2016-11-30 | Апейрон Биолоджикс Аг | Препараты и способы лечения gd2-положительного рака |
| US9840566B2 (en) | 2013-11-21 | 2017-12-12 | Apeiron Biologics Ag | Preparations and methods for treating a GD2 positive cancer |
| RU2663104C1 (ru) * | 2017-07-13 | 2018-08-01 | Общество с ограниченной ответственностью "Реал Таргет" | Получение пегилированных фрагментов gd2-специфичных антител, индуцирующих прямую клеточную гибель gd2-позитивных опухолевых клеток, и их применение в терапии gd2-позитивных опухолей |
| JP2020534370A (ja) * | 2017-09-21 | 2020-11-26 | ユーエムセー ユトレヒト ホールディング ベイフェイＵＭＣ Ｕｔｒｅｃｈｔ Ｈｏｌｄｉｎｇ Ｂ．Ｖ． | 神経芽腫の治療のための抗ｇｄ２抗体 |
| JP2023532753A (ja) * | 2020-07-06 | 2023-07-31 | イーユーエスエー ファーマ （ユーケー） リミテッド | Ｇｄ２陽性がんを治療するための方法 |
| WO2026053122A1 (en) * | 2024-09-04 | 2026-03-12 | Dana-Farber Cancer Institute, Inc. | Methods of treating retinoid responsive cancers |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863713A (en) | 1986-06-23 | 1989-09-05 | The Board Of Trustees Of Leland Stanford Jr. Univ. | Method and system for administering therapeutic and diagnostic agents |
| EP1345968A2 (en) | 2000-12-28 | 2003-09-24 | Altus Biologics Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
| US7455833B2 (en) | 2002-07-15 | 2008-11-25 | Board Of Regents, The University Of Texas System | Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| ATE471946T1 (de) | 2002-12-17 | 2010-07-15 | Merck Patent Gmbh | Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2 |
| CA2553883C (en) | 2004-01-22 | 2013-04-02 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Anti-cancer antibodies with reduced complement fixation |
| WO2007045465A1 (en) | 2005-10-21 | 2007-04-26 | F. Hoffmann-La Roche Ag | Method for the recombinant expression of a polypeptide |
| EP1916257A1 (en) | 2006-10-27 | 2008-04-30 | Charite-Universitätsmedizin Berlin | GD2 peptide mimotopes for anticancer vaccination |
| JP5654986B2 (ja) | 2008-06-30 | 2015-01-14 | モーフオテク・インコーポレーテツド | 抗ｇｄ２抗体並びにそれに関連する方法及び使用 |
| NZ603581A (en) | 2010-06-19 | 2015-05-29 | Sloan Kettering Inst Cancer | Anti-gd2 antibodies |
| JP5623999B2 (ja) | 2010-08-31 | 2014-11-12 | パナソニック株式会社 | 電子装置 |
| IN2014CN03887A (enExample) | 2011-10-27 | 2015-10-16 | Genmab As | |
| WO2013189516A1 (en) | 2012-06-18 | 2013-12-27 | Apeiron Biologics Ag | Method for treating a gd2 positive cancer |
| EP4218811A1 (en) | 2012-06-18 | 2023-08-02 | Apeiron Biologics AG | Method for treating a gd2 positive cancer |
| US9840566B2 (en) | 2013-11-21 | 2017-12-12 | Apeiron Biologics Ag | Preparations and methods for treating a GD2 positive cancer |
| EA201691055A1 (ru) | 2013-11-21 | 2016-11-30 | Апейрон Биолоджикс Аг | Препараты и способы лечения gd2-положительного рака |
-
2014
- 2014-11-21 EA EA201691055A patent/EA201691055A1/ru unknown
- 2014-11-21 HU HUE14802642A patent/HUE047920T2/hu unknown
- 2014-11-21 CA CA2930285A patent/CA2930285A1/en active Pending
- 2014-11-21 AU AU2014351796A patent/AU2014351796B2/en active Active
- 2014-11-21 HR HRP20200128TT patent/HRP20200128T1/hr unknown
- 2014-11-21 RS RS20200053A patent/RS59817B1/sr unknown
- 2014-11-21 LT LTEP14802642.0T patent/LT3071220T/lt unknown
- 2014-11-21 ES ES14802642T patent/ES2768649T3/es active Active
- 2014-11-21 EP EP19203951.9A patent/EP3620173A1/en not_active Withdrawn
- 2014-11-21 WO PCT/EP2014/075315 patent/WO2015075194A1/en not_active Ceased
- 2014-11-21 PT PT148026420T patent/PT3071220T/pt unknown
- 2014-11-21 EP EP14802642.0A patent/EP3071220B1/en active Active
- 2014-11-21 DK DK14802642.0T patent/DK3071220T3/da active
- 2014-11-21 NZ NZ720273A patent/NZ720273A/en unknown
- 2014-11-21 JP JP2016533187A patent/JP6693873B2/ja active Active
- 2014-11-21 PL PL14802642T patent/PL3071220T3/pl unknown
- 2014-11-21 SI SI201431460T patent/SI3071220T1/sl unknown
- 2014-11-21 SM SM20200027T patent/SMT202000027T1/it unknown
-
2019
- 2019-08-01 JP JP2019142173A patent/JP7139293B2/ja active Active
-
2020
- 2020-01-21 CY CY20201100048T patent/CY1122508T1/el unknown
- 2020-05-22 AU AU2020203346A patent/AU2020203346A1/en not_active Abandoned
- 2020-07-06 US US16/920,880 patent/US10995147B2/en active Active
-
2021
- 2021-03-03 US US17/190,792 patent/US11492412B2/en active Active
-
2023
- 2023-03-06 US US18/178,778 patent/US20240158530A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3620173A1 (en) | 2020-03-11 |
| EP3071220B1 (en) | 2019-12-25 |
| AU2014351796B2 (en) | 2020-02-27 |
| JP7139293B2 (ja) | 2022-09-20 |
| PT3071220T (pt) | 2020-02-03 |
| LT3071220T (lt) | 2020-02-25 |
| JP2016539122A (ja) | 2016-12-15 |
| ES2768649T3 (es) | 2020-06-23 |
| EA201691055A1 (ru) | 2016-11-30 |
| AU2014351796A2 (en) | 2016-08-11 |
| NZ720273A (en) | 2022-02-25 |
| EP3071220A1 (en) | 2016-09-28 |
| HK1223039A1 (en) | 2017-07-21 |
| AU2014351796A1 (en) | 2016-05-26 |
| SI3071220T1 (sl) | 2020-03-31 |
| US20200332021A1 (en) | 2020-10-22 |
| SMT202000027T1 (it) | 2020-03-13 |
| AU2020203346A1 (en) | 2020-06-11 |
| US20210221909A1 (en) | 2021-07-22 |
| PL3071220T3 (pl) | 2020-05-18 |
| JP2019218359A (ja) | 2019-12-26 |
| HRP20200128T1 (hr) | 2020-05-15 |
| US11492412B2 (en) | 2022-11-08 |
| DK3071220T3 (da) | 2020-02-10 |
| RS59817B1 (sr) | 2020-02-28 |
| US20240158530A1 (en) | 2024-05-16 |
| US10995147B2 (en) | 2021-05-04 |
| JP6693873B2 (ja) | 2020-05-13 |
| CA2930285A1 (en) | 2015-05-28 |
| WO2015075194A1 (en) | 2015-05-28 |
| HUE047920T2 (hu) | 2020-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123688T1 (el) | Μεθοδοι για τη θεραπευτικη αντιμετωπιση ογκων χρησιμοποιωντας αμφιειδικο αντισωμα cd3xcd20 | |
| JO3735B1 (ar) | مركبات ألكين بها استبدال رباعي واستخداماتها | |
| CY1122899T1 (el) | Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη | |
| EA201690905A1 (ru) | Специфические антитела против cd38 для лечения злокачественных новообразований у человека | |
| MX383691B (es) | Método de tratamiento de cáncer asociado con una mutación de ras. | |
| MX2018003594A (es) | Anticuerpo anti-garp. | |
| EA201500019A1 (ru) | Способ лечения gd2-положительного рака | |
| EA201790180A1 (ru) | Способы и терапевтические комбинации для лечения опухолей | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| BR112015019064A2 (pt) | métodos de tratamento de melanoma | |
| CY1120213T1 (el) | Antαγωνιστες φθοριωμενης ιντεγκρινης | |
| MX380273B (es) | Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp. | |
| MX2016010504A (es) | Metodos para el tratamiento de pacientes con hipercolesterolemia que no esta controlada adecuadamente por una terapia con estatinas de dosis moderada referencia cruzada a solicitudes relacionas. | |
| AR101740A1 (es) | Terapia de combinación y composiciones | |
| MX373231B (es) | Agente anticancerigeno. | |
| EA202090098A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
| BR112017018964A2 (pt) | uso de plinabulin e métodos para tratar tumor cerebral | |
| EA202090741A1 (ru) | Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака | |
| EA201591925A1 (ru) | Терапевтические композиции и их применение | |
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| EA201691055A1 (ru) | Препараты и способы лечения gd2-положительного рака | |
| EA202190102A1 (ru) | Коньюгаты антител к тканевым факторам с лекарственным средством и их применение в лечении рака | |
| EA201792256A1 (ru) | Соли и пролекарства 1-метил-d-триптофана | |
| MD20170025A2 (ro) | Tratamente terapeutice pe bază de anamorelin |